Previous 10 | Next 10 |
2023-11-13 17:18:11 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...
2023-11-13 08:43:06 ET More on VYNE Therapeutics Vyne Therapeutics jumps 52% on positive data from trials and $88M financing Seeking Alpha’s Quant Rating on VYNE Therapeutics Historical earnings data for VYNE Therapeutics Financial information for VYNE...
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VY...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
VYNE Therapeutics Inc. (VYNE) is expected to report $-0.76 for Q3 2023
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Th...
2023-11-03 14:08:27 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- The following companies were among the listings that we covered this week; Verve Therapeutics Inc (NASDAQ: VERV), Cellectis (NASDAQ: CLLS), Palantir Technologies (NYSE: PLTR), Werewolf Therapeutics (N...
2023-11-03 10:02:39 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: Cellectis, VYNE Therapeutics among healthcare movers
BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
2023-10-30 13:43:38 ET Gainers: Miromatrix Medical MIRO +216% . Eargo ( EAR ) +52% . Kaixin Auto Holdings ( KXIN ) +49% . Reviva Pharmaceuticals Holdings ( RVPH ) +45% . Conduit Pharmaceuticals ( CDT ) +40% . Primech Holdings Ltd...
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarter Phase 2b trial expected to enroll approximately 160 subjects with either active or stable nonsegmental vitiligo and will evaluate VYN201 gel in 1%, 2% and 3% concentrations compared t...
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD trial expected to start this quarter BRIDGEWATER, N.J., May 0...
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage ...